REAL WORLD FACTOR DISPENSATION AND EXPENDITURES IN US PATIENTS WITH HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE FACTOR IX REPLACEMENT PRODUCTS

被引：0
|
作者：
Chhabra, A. [1 ]
Spurden, D. [2 ]
Tortella, B. J. [3 ]
Fogarty, P. F. [3 ]
Pleil, A. [4 ]
Rubinstein, E. [1 ]
Alvir, J. [1 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Pfizer Ltd, Surrey, England
[3] Pfizer Inc, Collegeville, PA USA
[4] Pfizer Inc, San Diego, CA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.849
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY35
引用
收藏
页码：S111 / S111
页数：1
相关论文
共 50 条
  • [21] PK-guided switch from standard half-life to extended half-life factor VIII products
    Eduardo Megias-Vericat, Juan
    Bonanad, Santiago
    Martinez Garcia, Maria Fernanda
    Berrueco Moreno, Ruben
    Maria Mingot-Castellano, Eva
    Rodriguez Lopez, Manuel
    Canaro Hirnyk, Mariana
    Mateo Arranz, Jose
    Calvo Villas, Jose Manuel
    Haya, Saturnino
    Rosa Cid, Ana
    Iorio, Alfonso
    HAEMOPHILIA, 2020, 26 : 17 - 18
  • [22] PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
    Megias Vericat, J. E.
    Bonanad-Boix, S.
    Martinez Garcia, M. F.
    Berrueco, R.
    Mingot-Castellano, M. E.
    Rodriguez, M.
    Canaro, M.
    Mateu, J.
    Larrode, I.
    Haya, S.
    Santamaria, A.
    Mesegue, M.
    Albo, C.
    Palomero, A.
    Vilalta, N.
    Calvo, J. M.
    Cid, A. R.
    Poveda, J. L.
    Iorio, A.
    HAEMOPHILIA, 2020, 26 : 88 - 89
  • [23] Half-life extended factor VIII for the treatment of hemophilia A
    Tiede, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S176 - S179
  • [24] REAL-WORLD UTILIZATION AND COSTS OF EXTENDED HALF-LIFE FACTOR PRODUCTS IN PEDIATRIC HEMOPHILIA B PATIENTS ON PROPHYLAXIS THERAPY
    Yang, Kun
    Buckley, Brieana
    Mathison, Brent
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E74 - E74
  • [25] REAL-WORLD HEALTH CARE EXPENDITURE IN HEMOPHILIA A PATIENTS USING STANDARD AND EXTENDED HALF-LIFE RECOMBINANT FACTOR VIII PRODUCTS
    Chhabra, A.
    Tortella, B. J.
    Alvir, J.
    Estevez, C.
    Spurden, D.
    Hodge, J.
    McDonald, M.
    Pleil, A.
    VALUE IN HEALTH, 2017, 20 (09) : A892 - A892
  • [26] Long term realworld health care comparison of expenditures and international units dispensed of extended and standard half-life recombinant factor IX products in hemophilia B patients
    Tortella, B. J.
    Chhabra, A.
    Fogarty, P.
    Rubinstein, E.
    Young, L. J.
    Alvir, J.
    HAEMOPHILIA, 2019, 25 : 55 - 56
  • [27] USE OF EXTENDED HALF-LIFE FACTOR IX PRODUCTS IN REPRESENTATIVE PAEDIATRIC PATIENTS WITH SEVERE FACTOR IX DEFICIENCY
    Wu, John K.
    Chan, Anthony K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E96 - E96
  • [28] Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A
    Mannucci, Pier Mannuccio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 303 - 309
  • [29] Measurement of extended half-life recombinant factor IX products in clinical practice
    Bowyer, Annette E.
    Shepherd, M. Fiona
    Kitchen, Steve
    Maclean, Rhona M.
    Makris, Mike
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (02) : E46 - E49
  • [30] Transition considerations for extended half-life factor products
    Croteau, S. E.
    Neufeld, E. J.
    HAEMOPHILIA, 2015, 21 (03) : 285 - 288
12345